Experimental Autoimmune Myasthenia Gravis (EAMG) Model

Creative Bioarray provides in vivo pharmacology studies using a well-validated Experimental Autoimmune Myasthenia Gravis (EAMG) animal model. This model is designed to quickly assess the effectiveness of test compounds. Our scientific team is committed to working closely with you, from the initial study design through the final data analysis and reporting. By partnering with us, you can anticipate consistent and dependable outcomes for your research needs.

Myasthenia gravis (MG) is an autoimmune disorder characterized by the body's immune system attacking the acetylcholine receptor (AChR), muscle-specific kinase (MuSK), or other AChR-related proteins in the postsynaptic muscle membrane. This condition predominantly affects the voluntary muscles, particularly those governing the eyes, mouth, throat, and limbs. MG can occur at any age but is more prevalent among young women (ages 20 to 30) and men over 50. The EAMG model has significantly contributed to our understanding of the disease's pathophysiology, highlighting the roles of specific autoantibodies and T helper lymphocytes. The model, which can be induced in susceptible mice and rats to exhibit symptoms akin to those seen in humans, is invaluable for studying both muscular and immune system aspects of MG. It offers a platform for evaluating new treatment strategies, and suggesting potential avenues for disease prevention and modulation.

Fig. 1 Speculative mechanisms of AChR MG immunopathology. (Fichtner et al. 2020)

Our Experimental Autoimmune Myasthenia Gravis (EAMG) Model

• Available Animal

• Rat
• Mouse

• Modeling Method

Creative Bioarray has successfully developed an EAMG model in animals. This model is induced through immunization with a synthetic peptide that corresponds to amino acids 97-116 of the α subunit of the rat acetylcholine receptor (AChR), known as the R97-116 peptide.

• Endpoints

• Body weight
• Histology analysis: H&E staining
• Cytokine analysis
• Anti-AChR-antibody analysis
• qPCR or Western blot
• Other customized endpoints

Example Data

Fig. 2 CRIg/FH treatment ameliorates active EAMG. (A, B) CRIg/FH ameliorates active EAMG clinical outcomes significantly. The body weights (A) and clinical scores (B) were recorded every other day. (C, D) CRIg/FH reduces the serum levels of auto-antibodies. The serum antibody against AChR 97-116 peptide was measured by ELISA (C) and the apparent anti-AChR antibody concentration was determined by immunofluorescence with H9c2(2-1) cells expressing rat muscle AChR, corresponding to a concentration of mAb35, which gives an equivalent fluorescent signal on H9C2(2-1) cells (D). (Song et al. 2022)

Quotation and Ordering

Creative Bioarray boasts state-of-the-art pre-clinical technology platforms and a team of seasoned researchers and scientists. This combination enables us to offer an extensive array of services while maintaining consistently high-quality results and ensuring quick turnaround times. Our advanced capabilities and expert personnel make us a reliable partner for various pre-clinical and research needs, delivering precise and efficient outcomes across diverse projects.

References

1. Fichtner, M.L., et al. Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Frontiers in immunology, 2020, 11: 776.
2. Mantegazza, R., et al. Animal models of myasthenia gravis: utility and limitations. Int J Gen Med, 2016;9:53-64.
3. Song, J., et al. A targeted complement inhibitor CRIg/FH protects against experimental autoimmune myasthenia gravis in rats via immune modulation. Frontiers in Immunology, 2022, 13: 746068.

For research use only. Not for any other purpose.